title: Granuloma-forming interstitial pneumonia occurring one year after the start of everolimus therapy.
abstract: We experienced a case of interstitial lung disease (ILD) that occurred one year after the start of everolimus therapy for renal cell carcinoma. The pathological features included interstitial pneumonia with granuloma formation. Everolimus is known to cause ILD; however, its pathology is unclear. Granuloma-forming interstitial pneumonia associated with everolimus is uncommon, although it may be one of the pathological patterns associated with everolimus-induced ILD. This is a slow-onset case of everolimus-induced ILD in a patient with renal cell carcinoma. Physicians should thus be aware of the potential for the development of ILD at any time during the administration of everolimus therapy.
authors: Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Japan. yo-saito@nms.ac.jp
authors: Yoshinobu
authors: Y
authors: Saito
authors: Shinobu
authors: S
authors: Kunugi
authors: Yasutomo
authors: Y
authors: Suzuki
authors: Kousuke
authors: K
authors: Narita
authors: Yukiko
authors: Y
authors: Miura
authors: Yuji
authors: Y
authors: Minegishi
authors: Go
authors: G
authors: Kimura
authors: Yukihiro
authors: Y
authors: Kondo
authors: Arata
authors: A
authors: Azuma
authors: Yuh
authors: Y
authors: Fukuda
authors: Akihiko
authors: A
authors: Gemma
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy; D000068338:Everolimus; D015769:Granuloma, Respiratory Tract / Q000139:chemically induced* / Q000175:diagnosis*; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy; D017563:Lung Diseases, Interstitial / Q000139:chemically induced* / Q000175:diagnosis*; D008297:Male; D008875:Middle Aged; D020123:Sirolimus / Q000009:adverse effects / Q000031:analogs & derivatives*; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents; D000068338:Everolimus; D020123:Sirolimus